electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore, Inc. (Nasdaq: ECOR) plans to report its financial results for Q1 2020 on May 14, 2020, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results. The company specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies aimed at treating conditions like migraines and cluster headaches. With a commitment to improving patient outcomes, electroCore continues to innovate in the neurology and rheumatology sectors.